{"id":7507,"date":"2021-04-06T13:59:29","date_gmt":"2021-04-06T12:59:29","guid":{"rendered":"https:\/\/biggeesblog.cymru\/?p=7507"},"modified":"2021-04-06T14:53:39","modified_gmt":"2021-04-06T13:53:39","slug":"critical-update-on-mrna-injectables-collateral-damage-time-for-some-serious-thinking-by-the-public","status":"publish","type":"post","link":"https:\/\/biggeesblog.cymru\/index.php\/2021\/04\/06\/critical-update-on-mrna-injectables-collateral-damage-time-for-some-serious-thinking-by-the-public\/","title":{"rendered":"CRITICAL UPDATE On mRNA Injectables ‘collateral damage’ – Time For Some Serious Thinking By The Public"},"content":{"rendered":"
\n

Proof Of The Evil Intent As The mRNA “Vaccination” Programme Continues To Be Rolled Out.<\/h1>\n
\n

3,964 Dead 162,610 Injuries:<\/span> European Database of Adverse Drug Reactions for COVID-19 \u201cVaccines\u201d<\/h2>\n
\n
\n
By\u00a0Brian Shilhavy<\/a><\/span><\/em><\/div>\n
Global Research, March 25, 2021<\/span><\/em><\/div>\n
Health Impact News<\/a> 24 March 2021<\/span><\/em><\/div>\n<\/div>\n<\/div>\n
\n
\n
\n<\/div>\n<\/div>\n<\/div>\n
\n
\"\"<\/div>\n

Note: the tables from the original source are not displaying or have been removed.<\/p>\n

All the data indicated is for Pfizer, Moderna and Astrazeneca. 3,964 Dead 162,610 Injuries. to date.<\/strong><\/p>\n

 <\/p>\n

The Breakdown:<\/strong><\/h2>\n

Total reactions<\/strong>\u00a0for the experimental\u00a0vaccine\u00a0AZD1222 (CHADOX1 NCOV-\u00a0 (9) from Oxford\/ AstraZeneca: 451 deaths and 54,571 injuries to 13\/03\/2021<\/strong><\/p>\n

Total reactions<\/strong>\u00a0for the experimental mRNA vaccine\u00a0Tozinameran (code BNT162b2, Comirnaty)\u00a0 from\u00a0 BioNTech\/ Pfizer: 2,540 deaths and 102,100 injuries to 13\/03\/2021<\/strong><\/p>\n

Total reactions\u00a0<\/strong>for the experimental mRNA vaccine\u00a0mRNA-1273\u00a0(CX-024414)\u00a0from\u00a0Moderna:\u00a0973 deaths\u00a0and 5,939 injuries to 13\/03\/2021<\/strong><\/p>\n

The European database of suspected drug reaction reports,\u00a0EudraVigilance<\/a><\/span><\/span>, is now tracking reports of injuries and deaths following the experimental COVID-19 \u201cvaccines.\u201d<\/em><\/p>\n

Here is what\u00a0EudraVigilance<\/a><\/span><\/span>\u00a0states about their database:<\/p>\n

\n

This website was launched by the\u00a0European Medicines Agency<\/a><\/span><\/span>\u00a0in 2012\u00a0to provide public access to reports of suspected side effects\u00a0<\/strong>(also known as suspected adverse drug reactions). These reports are submitted electronically to\u00a0EudraVigilance<\/a><\/span><\/span>\u00a0by national medicines regulatory authorities and by pharmaceutical companies that hold marketing authorisations (licences) for the medicines.<\/p>\n

EudraVigilance is a system designed for collecting reports of suspected side effects. These reports are used for evaluating the benefits and risks of medicines during their development and monitoring their safety following their authorisation in the European Economic Area (EEA).\u00a0EudraVigilance has been in use since December 2001.<\/p>\n

This website was launched to comply with the\u00a0EudraVigilance Access Policy<\/a><\/span><\/span>, which was developed to improve public health by supporting the monitoring of the safety of medicines and to increase transparency for stakeholders, including the general public.<\/p>\n

The\u00a0Management Board of the European Medicines Agency<\/a><\/span><\/span> first approved the EudraVigilance Access Policy in December 2010. A revision was adopted by the Board in December 2015 based on the 2010 pharmacovigilance legislation. The policy aims to provide stakeholders such as national medicines regulatory authorities in the EEA, the European Commission, healthcare professionals, patients and consumers, as well as the pharmaceutical industry and research organisations, with access to reports on suspected side effects.<\/p>\n

Transparency is a key guiding principle of the Agency, and is pivotal to building trust and confidence in the regulatory process. By increasing transparency, the Agency is better able to address the growing need among stakeholders, including the general public, for access to information. (Source<\/a><\/span><\/span>.)<\/p>\n<\/blockquote>\n

\"\"<\/p>\n

Their report through March 13, 2021 lists 3,964 deaths and 162,610 injuries following injections of three experimental COVID-19 shots:<\/p>\n

COVID-19 MRNA VACCINE MODERNA (CX-024414)<\/a>,<\/span><\/span>\u00a0COVID-19 MRNA VACCINE PFIZER-BIONTECH (TOZINAMERAN<\/span><\/span>)<\/a>, and\u00a0COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)<\/a><\/span><\/span>.<\/p>\n

There is also data for a fourth experimental COVID \u201cvaccine,\u201d\u00a0COVID-19 VACCINE JANSSEN (AD26.COV2.S<\/a>)<\/span><\/span>. We have not included data from the Johnson and Johnson COVID shot in this report, but will do so in future reports.<\/p>\n

A\u00a0Health Impact News<\/em>\u00a0subscriber in Europe ran the reports for each of the three COVID-19 shots we are including here, and here is the summary data through March 13, 2021.<\/p>\n

Total reactions<\/strong> for the experimental mRNA\u00a0 vaccine\u00a0Tozinameran<\/b>\u00a0(code\u00a0BNT162b2<\/b>,\u00a0Comirnaty<\/b>) from\u00a0BioNTech<\/u><\/b>\/\u00a0<\/u><\/b>Pfizer:\u00a0<\/b>2,540\u00a0deaths\u00a0<\/strong><\/b>and 102,100 injuries to 13\/03\/2021<\/h4>\n

 <\/p>\n

\"\"<\/p>\n

COVID-19 MRNA VACCINE PFIZER-BIONTECH (TOZINAMERAN)<\/h4>\n
    \n
  1. 7,604 Blood and lymphatic system disorders incl.\u00a015 deaths<\/b><\/li>\n
  2. 4,636 Cardiac disorders incl.\u00a0276 deaths<\/b><\/li>\n
  3. 22 Congenital, familial and genetic disorders incl.\u00a02 deaths<\/b><\/li>\n
  4. 2,683 Ear and labyrinth disorders<\/li>\n
  5. 52 Endocrine disorders<\/li>\n
  6. 2,941 Eye disorders incl.\u00a02 deaths<\/b><\/li>\n
  7. 23,074 Gastrointestinal disorders incl.\u00a0125 deaths<\/b><\/li>\n
  8. 72,072 General disorders and administration site conditions incl.\u00a0957 deaths<\/b><\/li>\n
  9. 102 Hepatobiliary disorders incl.\u00a012 deaths<\/b><\/li>\n
  10. 1,928 Immune system disorders incl.\u00a011 deaths<\/b><\/li>\n
  11. 6,020 Infections and infestations incl.\u00a0275 deaths<\/b><\/li>\n
  12. 2,198 Injury, poisoning and procedural complications incl.\u00a032 deaths<\/b><\/li>\n
  13. 4,565 Investigations incl.\u00a0111 deaths<\/b><\/li>\n
  14. 1,567 Metabolism and nutrition disorders incl.\u00a049 deaths<\/b><\/li>\n
  15. 37,365 Musculoskeletal and connective tissue disorders incl.\u00a022 deaths<\/b><\/li>\n
  16. 55 Neoplasms benign, malignant and unspecified (incl cysts and polyps) incl.\u00a03 deaths<\/b><\/li>\n
  17. 44,993 Nervous system disorders incl.\u00a0185 deaths<\/b><\/li>\n
  18. 81 Pregnancy, puerperium and perinatal conditions incl.\u00a02 deaths<\/b><\/li>\n
  19. 57 Product issues<\/li>\n
  20. 3,742 Psychiatric disorders incl.\u00a028 deaths<\/b><\/li>\n
  21. 525 Renal and urinary disorders incl.\u00a037 deaths<\/b><\/li>\n
  22. 545 Reproductive system and breast disorders<\/li>\n
  23. 8,788 Respiratory, thoracic and mediastinal disorders incl.\u00a0294 deaths<\/b><\/li>\n
  24. 10,808 Skin and subcutaneous tissue disorders incl.\u00a018 deaths<\/b><\/li>\n
  25. 229 Social circumstances incl.\u00a06 deaths<\/b><\/li>\n
  26. 69 Surgical and medical procedures incl.\u00a04 deaths<\/b><\/li>\n
  27. 4,820 Vascular disorders incl.\u00a074 deaths<\/b><\/li>\n<\/ol>\n

    Total reactions<\/strong>\u00a0for the experimental mRNA vaccine\u00a0mRNA-1273\u00a0<\/b>(<\/b>CX-024414)<\/b>\u00a0from<\/b>\u00a0Moderna:\u00a0<\/b><\/b>973 deaths\u00a0<\/strong>and 5,939 injuries to 13\/03\/2021<\/h4>\n

    \"\"<\/p>\n

    COVID-19 MRNA VACCINE MODERNA (CX-024414)<\/h4>\n
      \n
    1. 330 Blood and lymphatic system disorders incl.\u00a09 deaths<\/b><\/li>\n
    2. 501 Cardiac disorders incl.\u00a096 deaths<\/b><\/li>\n
    3. 1 Congenital, familial and genetic disorders<\/li>\n
    4. 116 Ear and labyrinth disorders<\/li>\n
    5. 6 Endocrine disorders<\/li>\n
    6. 181 Eye disorders incl.\u00a02 deaths<\/b><\/li>\n
    7. 1,283 Gastrointestinal disorders incl.\u00a040 deaths<\/b><\/li>\n
    8. 4,198 General disorders and administration site conditions incl.\u00a0393 deaths<\/b><\/li>\n
    9. 21 Hepatobiliary disorders<\/li>\n
    10. 219 Immune system disorders incl.\u00a01 death<\/b><\/li>\n
    11. 515 Infections and infestations incl.\u00a057 deaths<\/b><\/li>\n
    12. 236 Injury, poisoning and procedural complications incl.\u00a016 deaths<\/b><\/li>\n
    13. 411 Investigations incl.\u00a036 deaths<\/b><\/li>\n
    14. 165 Metabolism and nutrition disorders incl.\u00a018 deaths<\/b><\/li>\n
    15. 1,727 Musculoskeletal and connective tissue disorders incl. 23 deaths<\/b><\/li>\n
    16. 12 Neoplasms benign, malignant and unspecified (incl cysts and polyps) incl.\u00a03 deaths<\/b><\/li>\n
    17. 2,324 Nervous system disorders incl.\u00a0111 deaths<\/b><\/li>\n
    18. 15 Pregnancy, puerperium and perinatal conditions<\/li>\n
    19. 4 Product issues<\/li>\n
    20. 271 Psychiatric disorders incl.\u00a014 deaths<\/b><\/li>\n
    21. 93 Renal and urinary disorders incl.\u00a010 deaths<\/b><\/li>\n
    22. 34 Reproductive system and breast disorders incl.\u00a01 death<\/b><\/li>\n
    23. 817 Respiratory, thoracic and mediastinal disorders incl.\u00a093 deaths<\/b><\/li>\n
    24. 740 Skin and subcutaneous tissue disorders incl.\u00a011 deaths<\/b><\/li>\n
    25. 48 Social circumstances incl. 3 deaths<\/b><\/li>\n
    26. 40 Surgical and medical procedures incl.\u00a04 deaths<\/b><\/li>\n
    27. 368 Vascular disorders incl.\u00a032 deaths<\/b><\/li>\n<\/ol>\n

      Total reactions<\/strong>\u00a0for the experimental\u00a0vaccine\u00a0<\/b>AZD1222<\/b>\u00a0<\/b>(CHADOX1 NCOV-19)<\/b>\u00a0from\u00a0<\/b>Oxford<\/b>\/<\/b>\u00a0<\/b>AstraZeneca<\/b>:\u00a0451 deaths\u00a0<\/strong>and 54,571 injuries to 13\/03\/2021<\/h4>\n

      \"\"<\/p>\n

      COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)<\/h4>\n
        \n
      1. 1,180 Blood and lymphatic system disorders incl.\u00a011 deaths<\/b><\/li>\n
      2. 2,080 Cardiac disorders incl.\u00a063 deaths<\/b><\/li>\n
      3. 17 Congenital, familial and genetic disorders<\/li>\n
      4. 1,237 Ear and labyrinth disorders<\/li>\n
      5. 41 Endocrine disorders<\/li>\n
      6. 1,977 Eye disorders incl. 1\u00a0death<\/b><\/li>\n
      7. 17,491 Gastrointestinal disorders incl.\u00a015 deaths<\/b><\/li>\n
      8. 42,367 General disorders and administration site conditions incl.\u00a0198 deaths<\/b><\/li>\n
      9. 32 Hepatobiliary disorders incl.\u00a01 death<\/b><\/li>\n
      10. 578 Immune system disorders<\/li>\n
      11. 3,340 Infections and infestations incl.\u00a046 deaths<\/b><\/li>\n
      12. 853 Injury, poisoning and procedural complications incl.\u00a02 deaths<\/b><\/li>\n
      13. 2,384 Investigations incl.\u00a03 deaths<\/b><\/li>\n
      14. 2,676 Metabolism and nutrition disorders incl.\u00a05 deaths<\/b><\/li>\n
      15. 22,858 Musculoskeletal and connective tissue disorders incl.\u00a04 deaths<\/b><\/li>\n
      16. 19 Neoplasms benign, malignant and unspecified (incl cysts and polyps) incl.\u00a02 deaths<\/b><\/li>\n
      17. 32,490 Nervous system disorders incl.\u00a041 deaths<\/b><\/li>\n
      18. 22 Pregnancy, puerperium and perinatal conditions<\/li>\n
      19. 11 Product issues<\/li>\n
      20. 3,105 Psychiatric disorders incl.\u00a03 deaths<\/b><\/li>\n
      21. 560 Renal and urinary disorders incl.\u00a04 deaths<\/b><\/li>\n
      22. 266 Reproductive system and breast disorders<\/li>\n
      23. 4,293 Respiratory, thoracic and mediastinal disorders incl.\u00a033 deaths<\/b><\/li>\n
      24. 6,815 Skin and subcutaneous tissue disorders incl.\u00a02 deaths<\/b><\/li>\n
      25. 99 Social circumstances incl.\u00a02 deaths<\/b><\/li>\n
      26. 138 Surgical and medical procedures incl.\u00a04 deaths<\/b><\/li>\n
      27. 1,656 Vascular disorders incl.\u00a011 deaths<\/b><\/li>\n<\/ol>\n\n\n\n
         <\/p>\n

        This is public information funded by the European Medicines Agency (EMA<\/span>).<\/span><\/span><\/p>\n

        But it is obviously being censored by the corporate media.<\/span><\/p>\n

        Ask yourself WHY?<\/strong><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

         <\/p>\n

        Heed The Warnings From Professionals<\/span><\/h4>\n